摘要
造血干细胞移植是治疗恶性血液病的有效措施,由于移植后免疫抑制剂的使用,机体免疫功能受到影响,病毒感染在造血干细胞移植后具有很高的发生率。EB病毒(Epstein-Barr virus,EBV)感染是移植后常见的病毒感染之一,其诱发的移植后淋巴细胞增殖性疾病虽然发生率低,但疾病进展快,死亡率高。T淋巴细胞在机体抗病毒免疫中发挥着重要作用,基于病毒特异性细胞毒性T淋巴细胞(cytotoxic T lymphocyte,CTL)的细胞免疫治疗显示了很好的安全性及有效性。本文回顾了近几年国内外细胞免疫疗法治疗EB病毒感染的最新进展,包括制备方法的改进、新分离方法的使用及第三方CTL的应用,并探讨EB病毒感染细胞免疫治疗的临床应用前景及存在的问题。
Hematopoietic stem cell transplantation is an ettective method for treatment of hematologic malignancies.Due to the use of immunosuppressive agents and a long time of immune restoration after transplantation,the incidence of virus infection is high.Epstein-Barr virus(EBV) infection is a common viral infection after transplantation.In spite of the low incidence of post transplantation lymphoproliferative disorder(PTLD) caused by EBV,this disease is characterized by rapid progression and high mortality.T lymphocytes play an important role in anti-viral immunity,and the cellular immune therapy based on virus-specific cytotoxic T lymphocyte(CTL) is safe and efficient.This review presents the domestic and foreign advances in cellular immune treatment against EBV infection and explores the clinical application prospects as well as problems.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2015年第6期1763-1768,共6页
Journal of Experimental Hematology
基金
医院创新基金资助(201385)
关键词
EB病毒
造血干细胞移植
移植后淋巴细胞增殖性疾病
细胞免疫治疗
Epstein-Barr virus
hematopoietic stem cell transplantation
post transplantation lymphoproliferative disorder
cellular immune therapy